

**AMBALAL SARABHAI ENTERPRISES LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December, 2009**

(Rs In Lakhs)

Particulars	Three months ended	Corresponding three months in previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous accounting year ended
	31-12-2009 Unaudited	31-12-2008 Unaudited	31-12-2009 Unaudited	31-12-2008 Unaudited	31-3-2009 Audited
	<b>As per Limited Review</b>				
1 (a) Net Sales / Income from operations	1,420.39	1,388.90	4,131.02	4,622.99	6,250.95
(b) Other Operating Income	-	-	-	-	-
2. Expenditure					
a)( Increase) / decrease in Stock in Trade & Work In Progress	(23.11)	(105.18)	(95.19)	(187.93)	24.04
b) Consumption of Raw Materials	168.16	205.43	529.80	637.89	768.48
c) Purchase of Traded Goods	850.17	963.16	2,424.85	3,041.83	3,985.90
d) Employees Cost	564.00	495.26	1,668.18	1,761.73	3,530.67
e) Depreciation	41.25	36.43	139.60	138.59	203.76
f) Other Expenditure	293.36	287.73	889.84	1,283.00	9,536.27
g) Total	1,893.83	1,882.83	5,557.08	6,675.11	18,049.12
3. Profit/(Loss) from operations before other income, interest and exceptional items(1-2)	(473.44)	(493.93)	(1,426.06)	(2,052.12)	(11,798.17)
4. Other income	41.90	60.20	125.01	281.08	315.82
5.Profit/(Loss) before interest and exceptional items(3+4)	(431.54)	(433.73)	(1,301.05)	(1,771.04)	(11,482.35)
6. Interest	27.26	37.01	173.61	468.70	1,120.06
7.Profit/(Loss) after interest but before exceptional items(5-6)	(458.80)	(470.74)	(1,474.66)	(2,239.74)	(12,602.41)
8. Exceptional items	-	-	-	-	-
9.Profit/( loss) from ordinary activities before tax(7+8)	(458.80)	(470.74)	(1,474.66)	(2,239.74)	(12,602.41)
10.Tax Expenses [ Provision for FBT & Current Tax )	-	6.35	-	19.05	718.68
11.Profit/(Loss) from Ordinary Activities after Tax (9-10)	(458.80)	(477.09)	(1,474.66)	(2,258.79)	(13,321.09)
12. Extraordinary Income/(Expenses) (Net)	(233.99)	5,249.10	2,666.76	14,326.10	14,406.23
13. Net Profit/(Loss) for the period (11-12)	(692.79)	4,772.01	1,192.10	12,067.31	1,085.14
14. Paid-up Equity Share Capital ( Face Value of Rs 10 per share)	7,663.33	7,663.33	7,663.33	7,663.33	7,663.33
15. Reserves excluding revaluation reserves					(2,675.46)
16.Earning Per share(EPS Rs..)					
a. Basic and diluted Earnings Per Share before extraordinary items (not to be annualised).	(0.60)	(0.62)	(1.92)	(2.95)	(17.38)
b.Basic and diluted Earnings Per Share after extraordinary items (not to be annualised).	(0.90)	6.23	1.56	15.75	1.42
17.Public Shareholding					
No of Shares	53314345	53314345	53314345	53314345	56314345
Percentage of Shareholding	69.57%	69.57%	69.57%	69.57%	69.57%
18. Promoters & Promoters Group					
a) Pledged share holding & encumbered					
No of Shares	NII	NA	NII	NA	NII
Percentage of Share ( as a percentage of the total share holding of promoters and promoters group)	NII	NA	NII	NA	NII
Percentage of Share ( as a percentage of the total share Capital of the company)	NII	NA	NII	NA	NII
b) Non encumbered					
No of Shares	23318951	NA	23318951	NA	23318951
Percentage of Share ( as a percentage of the total share holding of promoters and promoters group)	100%	NA	100%	NA	100%
Percentage of Share ( as a percentage of the total share Capital of the company)	30.43%	NA	30.43%	NA	30.43%

15


					(Rs in Lakhs)
Segment wise Revenue, Results and Capital Employed					
Particulars	Three months ended	Corresponding three months in previous year	Year to date figures for Current period ended	Year to date figures for Previous period ended	Previous Accounting year ended
	31-12-2009	31-12-2008	31-12-2009	31-12-2008	31-03-2009
<b>1.SEGMENT REVENUE</b> net sales /income from segment should be disclosed under this head)					
a.PHARMECEUTICALS	647.56	582.38	1,993.09	2,279.65	2,688.34
b. ELECTRONICS	772.83	806.52	2,137.93	2,343.34	3,562.81
<b>TOTAL</b>	<b>1,420.39</b>	<b>1,388.90</b>	<b>4,131.02</b>	<b>4,622.99</b>	<b>6,250.95</b>
<b>LESS INTER SEGMENT REVENUE</b>		-	-		-
<b>NET SALES/INCOME FROM OPERATIONS</b>	<b>1,420.39</b>	<b>1,388.90</b>	<b>4,131.02</b>	<b>4,622.99</b>	<b>6,250.95</b>
<b>2.SEGMENT RESULTS</b>					
<b>PROFIT/(LOSS) BEFORE INTEREST &amp; TAX FOR EACH SEGMENT</b>					
a. PHARMACEUTICALS	(504.89)	(464.35)	(1,465.93)	(1,844.20)	(11,790.96)
b. ELECTRONICS	73.35	30.62	164.88	73.16	(7.21)
<b>TOTAL</b>	<b>(431.54)</b>	<b>(433.73)</b>	<b>(1,301.05)</b>	<b>(1,771.04)</b>	<b>(11,798.17)</b>
<b>LESS: INTEREST</b>	<b>27.26</b>	<b>37.01</b>	<b>173.61</b>	<b>468.70</b>	<b>1,120.06</b>
<b>TOTAL</b>	<b>(458.80)</b>	<b>(470.74)</b>	<b>(1,474.66)</b>	<b>(2,239.74)</b>	<b>(12,918.23)</b>
<b>OTHER UNALLOCABLE INCOME NET OF UNALLOCABLE EXPENDITURE</b>	<b>(233.99)</b>	<b>5,249.10</b>	<b>2,666.76</b>	<b>14,326.10</b>	<b>14,722.05</b>
<b>TOTAL PROFIT/(LOSS) BEFORE TAX</b>	<b>(692.79)</b>	<b>4,778.36</b>	<b>1,192.10</b>	<b>12,086.36</b>	<b>1,803.82</b>
<b>PROVISION FOR TAXATION</b>	-	-	-	-	718.68
<b>NET PROFIT/(LOSS)</b>	<b>(692.79)</b>	<b>4,778.36</b>	<b>1,192.10</b>	<b>12,086.36</b>	<b>1,085.14</b>
<b>3. CAPITAL EMPLOYED</b> (Segment Assets-Segment Liabilities)					
1. PHARMACEUTICALS	(1,235.82)	13,202.67	(1,235.82)	13,202.67	15.36
2. ELECTRONICS	2,097.90	2,409.14	2,097.90	2,409.14	2,071.61
<b>TOTAL CAPITAL EMPLOYED IN SEGMENTS</b>	<b>862.09</b>	<b>15,611.81</b>	<b>862.09</b>	<b>15,611.81</b>	<b>2,086.97</b>
<b>UNALLOCABLE CORPORATE ASSETS</b>					
<b>LESS CORPORATE LIABILITIES</b>	<b>6,641.36</b>	<b>8,312.62</b>	<b>6,641.36</b>	<b>8,312.62</b>	<b>4,109.75</b>
<b>TOTAL</b>	<b>7,503.45</b>	<b>23,924.43</b>	<b>7,503.45</b>	<b>23,924.43</b>	<b>6,196.72</b>

19

**NOTES:**

- 1) The Limited Review of the above Unaudited financial Results as required under clause 41 of the listing agreement has been carried out by the statutory auditors.
- 2) The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 19/04/2010.
- 3) Previous year's/quarter's figures have been rearranged and regrouped where ever necessary.
- 4) The Company had no pending Investors' complaints as on 01-10-09. During current quarter, the Company has received five complaints which are settled during the quarter. No complaint is lying unresolved at the end of the quarter.
- 5) Provision for taxation if any, will be made at the end of the year.
- 6) Extraordinary Expense : The extraordinary expenditure represents write off in respect of consideration not receivable by the Company for transfer of part of factory land in terms of agreement executed by the Company in this regard.
- 7) With reference to the qualification in the Auditors Report as on 31.03.09, the Board submits that having regard to the future economic benefits based on the company's business plans, the Company does not expect any impairment in respect of goodwill.

For Ambalal Sarabhai Enterprises Limited

  
Chairman

Date: 19.04.2010  
Place: Ahmedabad